Gliknik, Inc. and Pfizer have entered into an exclusive worldwide licensing agreement under which Pfizer receives rights to GL-2045, a recombinant stradomer drug candidate designed to replace and improve pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising preclinical results as a potential treatment for a variety of autoimmune diseases, including those in which IVIG is clinically used.
 
Pfizer will receive exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik will receive an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments, as well as royalties on sales.
 
“GL-2045 is the first of several innovative drug candidates Gliknik is advancing for people with autoimmune diseases and cancer,” said Gliknik chief executive officer David S. Block. “We selected Pfizer as our partner to progress GL-2045 from among several interested and capable parties because of its exceptional development, manufacturing and commercial capabilities.”
 
“People with certain autoimmune diseases have limited treatment options, difficult regimens and often a poor prognosis,” said Jose Carlos Gutierrez-Ramos, Ph.D., group senior vice president and head of Biotherapeutics R&D at Pfizer. “Pooled IVIG has a long history of use but has a number of limitations. We are pleased to partner with Gliknik on this novel therapeutic approach which may provide an important new option in managing debilitating autoimmune diseases.”